Home » Advocacy » Letters, Testimony & Comments

Letters, Testimony & Comments

Cellulosic Biofuel: BIO Asks Congress to Fund Reverse Auction
March 23, 2010
A letter from the Biotechnology Industry Organization (BIO), 25x'25, the Energy Future Coalition (EFC), the Renewable Fuels Association (RFA), the Environmental and Energy Study Institute (EESI), and the American Coalition for Ethanol (ACE)...
BIO Priorities in FY2011 Labor, Health and Human Services, Education and Related Agencies Appropriations Act
March 23, 2010
Letters urging funding for public health programs and initiatives which utilize biotechnology to help meet our nation’s unmet medical needs.
Draft Guidance on IRB Continuing Review After Clinical Investigation Approval
March 15, 2010
BIO's comments regarding Inclusion of TRICARE Retail Pharmacy Program in Federal Procurement of Pharmaceuticals
March 11, 2010
Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products
March 8, 2010
BIO Priorities in FY2011 Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Act
March 5, 2010
BIO Priorities in FY2011 Energy & Water Appropriations Bill
March 5, 2010
BIO Priorities in FY2011 State, Foreign Relations & Related Programs Appropriations Act
March 5, 2010
Comments on the Centers for Medicare & Medicaid Services’ (CMS) Draft 2011 Call Letter
March 5, 2010
Re: Draft 2011 Part D Call Letter Dear Acting Administrator Frizzera: The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the Centers for Medicare & Medicaid Services’ (CMS) Draft 2011 Call Letter....
Letter regarding BIO comments on Draft Environmental Impact Statement; Determination of Regulated Status of Alfalfa Genetically Engineered for Tolerance to the Herbicide Glyphosate
March 3, 2010
Algae Biofuels: BIO Asks for Parity in Tax Code
March 3, 2010
Letter to Senate Finance Committee Chairman Max Baucus (D-Mont.) and Ranking Member Charles Grassley (R-Iowa), asking for recognition of algae biofuels as an advanced biofuel in tax codes.
Proposed Rule on Informed Consent Elements
March 1, 2010
BIO Comments to FDA Regarding Promotion of Food and Drug Administration-Regulated Medical Products Using the Internet and Social Media Tools [Docket No. FDA-2009-N-0441]
February 26, 2010
Statement Before the Advisory Panel on Ambulatory Payment Classification Groups
February 19, 2010
Intellectual Property: BIO notes international trends that could undermine IP protection
February 18, 2010
BIO submits comments on the annual Special 301 Review: Identification of Countries Under Section 182 of the Trade Act of 1974, identifying countries of particular concern on intellectual property protection.
Letter, Identification of Countries involving the Special 301 provisions
February 18, 2010
Intellectual Property Innovation and Chair of the Special 301 Committee Office of the United States Trade Representative Washington, D.C. Submitted electronically to http://www.regulations.gov, docket number USTR-2010-0003 Re: 2010 Special...
Genetically Modified Crops: Presence of Genetically Modified Crop DNA in Food
February 10, 2010
Intellectual Property: Gene Patents and Licensing and Their Impace on Genetic Tests
February 4, 2010
Comments to Health and Human Services (HHS) urging rejection of Report Recommendations by Secretary’s Advisory Committee. on Genetics, Health and Society’s (SACGHS).
Sign-on Letter to HHS Regarding Advisory Committee Report on Gene Patents and Patient Access to Genetic Tests
February 4, 2010
Assay Development for Immunogenicity Testing of Therapeutic Proteins
February 2, 2010